Skip to main content
Clinical Trials/CTRI/2019/05/018990
CTRI/2019/05/018990
Completed
Phase 4

A comparative study of the safety, efficacy, quality of life outcome and pharmacoeconomics of levetiracetam with controlled-release carbamazepine in patients of new onset focal seizures

Institutional sponsored0 sites74 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: G400- Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onsetHealth Condition 2: G402- Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizuresHealth Condition 3: G401- Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures
Sponsor
Institutional sponsored
Enrollment
74
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
September 14, 2020
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Institutional sponsored

Eligibility Criteria

Inclusion Criteria

  • The study will include all the newly diagnosed consenting adult patients of focal seizures without any other co\-morbidities

Exclusion Criteria

  • Patients not willing to give written informed consent.
  • Pregnant females.
  • Patients already on treatment with study drugs.
  • Patients of seizures others than focal seizures.
  • Patients of head trauma within past one month.
  • Patients with known contraindication or refractoriness to study drugs.

Outcomes

Primary Outcomes

Not specified

Similar Trials